Tagrisso® (osimertinib) receives full Health Canada approval for targeted treatment of non-small cell lung cancer

Wednesday, January 31, 2018 Cancer News
Email Print This Page Comment bookmark
Font : A-A+

____________________________________1 TAGRISSO™ (osimertinib) Product Monograph. Accessed January 26, 2018: https://www.astrazeneca.ca/content/dam/az-ca/downloads/productinformation/tagrisso-product-monograph-en.pdf 

2 Lung Cancer Canada, The Faces of Lung Cancer Report 2017. Accessed January 26, 2018:  http://www.lungcancercanada.ca/LungCancerCanada/media/Documents/Faces-of-Lung-Cancer-Report-2017.pdf     

3 Molina JR, et al. Non-small cell lung cancer: Epidemiology, risk factors, treatment and survivorship. Mayo Clin Proc. 2008 May; 83(5): 584-594.

4 Ellison G, et al. EGFR mutation testing in lung cancer: a review of available methods and their use for analysis of tumour tissue and cytology samples. J Clin Pathol. 2013; 66: 79-89.



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store